<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20110103005536N10</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-04-01</date_registration>
      <primary_sponsor>Islamic Azad University</primary_sponsor>
      <public_title>Investigating the effect of intravenous ondansetron on arterial blood pressure changes and heart rate in patient undergoing surgery with spinal anesthesia</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of intravenous ondansetron on arterial blood pressure changes and heart rate in patient undergoing inguinal hernia repair surgery with spinal anesthesia</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-04-18</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>130</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/55223</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The sample size in this study is 130 participants who will be studied by simple random sampling method. For this purpose, to place patients in the case or control group, we will use the function of generating random numbers in Excel software and with Depending on whether the number is even or odd, we place the sample in the case or control group. (Even numbers will be in the case group and odd numbers will be in the control group) also, in order to hide the random sequence in the participants, from the opaque envelopes sealed with random sequence (SNOSE) using the cards related to each group, based on the order of entry of the eligible participants in the study, the envelopes are opened in order. And the group assigned to that participant is identified, Blinding description: This study is double blind and both the patient and the injector (outcome assessor) will be unaware of the contents of the syringe and only the syringe number will be recorded in the relevant checklist. The syringe may contain the drug or distilled water (placebo).</study_design>
      <phase>3</phase>
      <hc_freetext>Spinal anesthesia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: After placing the patient on the operating table and before performing spinal anesthesia, systolic blood pressure, diastolic blood pressure, moderate blood pressure, using non-invasive measurement method, and heart rate, are measured using electrocardiogram monitoring and checked. The list will be recorded as the base parameters. Then, in the case group, 4 mg of ondansetron from Alborz company will be injected by an anesthesiologist within 30 seconds. Then, all patients will be placed under spinal anesthesia from the L4-L5 or L3-L4 space with 15 mg of bupivacaine 0.5 using a 25-gauge needle. Immediately after spinal anesthesia and placing the patient in the open arch position, systolic pressure, diastolic blood pressure, moderate blood pressure and heart rate will be measured again and recorded in a questionnaire. All of the above parameters are measured and recorded immediately after anesthesia,. Fifth minute, قه tenth minute, fifteenth minute, twentieth minute, twenty-fifth minute and thirty minutes after spinal anesthesia. In case of nausea during the operation, which is determined by asking the patient. This issue is recorded in the questionnaire. In case of vomiting, this issue is also recorded in the questionnaire. The occurrence of any shivering will also be recorded in the questionnaire. Intervention 2: Control group: After placing the patient on the operating table and before performing spinal anesthesia, systolic blood pressure, diastolic blood pressure, moderate blood pressure, using non-invasive measurement method, and heart rate, are measured using electrocardiogram monitoring and checked. The list will be recorded as the base parameters. Then in the control group, 4 ml of distilled water (placebo) will be injected by an anesthesiologist in 30 seconds. Then, all patients will be placed under spinal anesthesia from the L4-L5 or L3-L4 space with 15 mg of bupivacaine 0.5 using a 25-gauge needle. Immediately after spinal anesthesia and placing the patient in the open arch position, systolic pressure, diastolic blood pressure, moderate blood pressure and heart rate will be measured again and recorded in a questionnaire. All of the above parameters are measured and recorded immediately after anesthesia,. Fifth minute, قه tenth minute, fifteenth minute, twentieth minute, twenty-fifth minute and thirty minutes after spinal anesthesia. In case of nausea during the operation, which is determined by asking the patient. This issue is recorded in the questionnaire. In case of vomiting, this issue is also recorded in the questionnaire. The occurrence of any shivering will also be recorded in the questionnaire.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All research data can be shared after identifying individuals

When:
Start the access period after printing the results

To whom:
All researchers in the field of anesthesia and only by mentioning the source

Conditions:
It can be used only for therapeutic and research purposes and by mentioning the source

Where to obtain:
Dr. Mohammadreza Rafiei

How to obtain:
Send a request email to Dr. Rafiei and receive the data if the user approves

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Mohammadreza Rafiei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Aja univercity of medical science, Etemadzadeh St., West Fatemi Ave.,</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411718541</zip>
        <telephone>+98 21 8609 6350</telephone>
        <email>mo_rafiei@armyums.ac.ir</email>
        <affiliation>Artesh University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohamadreza Rafiei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Aja univercity of medical science, Etemadzadeh St., West Fatemi Ave.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411718541</zip>
        <telephone>+98 21 8802 8933</telephone>
        <email>mo_rafiei@armyums.ac.ir</email>
        <affiliation>Artesh University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The patient is a candidate for spinal hernia repair surgery by spinal anesthesia
The patient has consented to spinal anesthesia</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>The patient has a contraindication to spinal anesthesia.
The patient has hypertension
The patient has a history of heart disease
The patient has a history of migraine
The patient has a history of allergy to ondansetron
The patient has a history of taking any medication that changes blood pressure or heart rate</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: After placing the patient on the operating table and before performing spinal anesthesia, systolic blood pressure, diastolic blood pressure, moderate blood pressure, using non-invasive measurement method, and heart rate, are measured using electrocardiogram monitoring and checked. The list will be recorded as the base parameters. Then, in the case group, 4 mg of ondansetron from Alborz company will be injected by an anesthesiologist within 30 seconds. Then, all patients will be placed under spinal anesthesia from the L4-L5 or L3-L4 space with 15 mg of bupivacaine 0.5 using a 25-gauge needle. Immediately after spinal anesthesia and placing the patient in the open arch position, systolic pressure, diastolic blood pressure, moderate blood pressure and heart rate will be measured again and recorded in a questionnaire. All of the above parameters are measured and recorded immediately after anesthesia,. Fifth minute, قه tenth minute, fifteenth minute, twentieth minute, twenty-fifth minute and thirty minutes after spinal anesthesia. In case of nausea during the operation, which is determined by asking the patient. This issue is recorded in the questionnaire. In case of vomiting, this issue is also recorded in the questionnaire. The occurrence of any shivering will also be recorded in the questionnaire.</i_keyword>
      <i_keyword>Control group: After placing the patient on the operating table and before performing spinal anesthesia, systolic blood pressure, diastolic blood pressure, moderate blood pressure, using non-invasive measurement method, and heart rate, are measured using electrocardiogram monitoring and checked. The list will be recorded as the base parameters. Then in the control group, 4 ml of distilled water (placebo) will be injected by an anesthesiologist in 30 seconds. Then, all patients will be placed under spinal anesthesia from the L4-L5 or L3-L4 space with 15 mg of bupivacaine 0.5 using a 25-gauge needle. Immediately after spinal anesthesia and placing the patient in the open arch position, systolic pressure, diastolic blood pressure, moderate blood pressure and heart rate will be measured again and recorded in a questionnaire. All of the above parameters are measured and recorded immediately after anesthesia,. Fifth minute, قه tenth minute, fifteenth minute, twentieth minute, twenty-fifth minute and thirty minutes after spinal anesthesia. In case of nausea during the operation, which is determined by asking the patient. This issue is recorded in the questionnaire. In case of vomiting, this issue is also recorded in the questionnaire. The occurrence of any shivering will also be recorded in the questionnaire.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Systolic blood pressure. Timepoint: Before, during and after spinal anesthesia. Method of measurement: NIBP (non invasive blood pressure) monitoring.</prim_outcome>
      <prim_outcome>Diastolic blood pressure. Timepoint: Before, during and after spinal anesthesia. Method of measurement: NIBP (non invasive blood pressure) monitoring.</prim_outcome>
      <prim_outcome>Mean arterial pressure. Timepoint: Before, during and after spinal anesthesia. Method of measurement: NIBP (non invasive blood pressure) monitoring.</prim_outcome>
      <prim_outcome>Hearth rate. Timepoint: Before, during and after spinal anesthesia. Method of measurement: Patient's monitoring.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Nausea and vomiting. Timepoint: After spinal anesthesia. Method of measurement: Clinical observation.</sec_outcome>
      <sec_outcome>Chills. Timepoint: After the intervention. Method of measurement: Clinical observation.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Islamic Azad University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-01-01</approval_date>
        <contact_name>Ethics Committee of Islamic Azad University, Najafabad Branch</contact_name>
        <contact_address>Daneshgah Blvd. Najaf abad Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
